1. Home
  2. GKOS vs MIRM Comparison

GKOS vs MIRM Comparison

Compare GKOS & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Glaukos Corporation

GKOS

Glaukos Corporation

HOLD

Current Price

$116.56

Market Cap

6.0B

Sector

Health Care

ML Signal

HOLD

Logo Mirum Pharmaceuticals Inc.

MIRM

Mirum Pharmaceuticals Inc.

HOLD

Current Price

$93.85

Market Cap

5.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GKOS
MIRM
Founded
1998
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.0B
5.7B
IPO Year
2015
2019

Fundamental Metrics

Financial Performance
Metric
GKOS
MIRM
Price
$116.56
$93.85
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
14
12
Target Price
$133.07
$115.33
AVG Volume (30 Days)
661.7K
828.1K
Earning Date
04-29-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
74.59
EPS
N/A
N/A
Revenue
$507,442,000.00
$19,138,000.00
Revenue This Year
$23.30
$26.22
Revenue Next Year
$27.43
$22.04
P/E Ratio
N/A
N/A
Revenue Growth
32.33
N/A
52 Week Low
$73.16
$37.83
52 Week High
$130.23
$109.28

Technical Indicators

Market Signals
Indicator
GKOS
MIRM
Relative Strength Index (RSI) 58.27 50.50
Support Level $104.72 $85.35
Resistance Level $123.16 $96.65
Average True Range (ATR) 4.70 3.79
MACD 1.71 0.88
Stochastic Oscillator 69.51 60.83

Price Performance

Historical Comparison
GKOS
MIRM

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.

Share on Social Networks: